N/A
N=74
Progression Delaying Effect of Escitalopram in Alzheimer's Disease
Alzheimer's Disease
Bottom Line
View on ClinicalTrials.gov: NCT00702780 ↗Enrolled (actual)
74
Serious AEs
6.8%
Results posted
Jun 2014
Primary outcome: Primary: % Change of Hippocampus Volume — -7.63; -7.28 percentage of change
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- escitalopram (Drug); placebo (Drug)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- All
- Sponsor
- Seoul National University Hospital
- Primary completion
- Sep 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY % Change of Hippocampus Volume |
-7.63; -7.28 | — |
| PRIMARY % Change of Whole Brain Volume |
-3.27; -2.30 | — |
Summary
This study aimed to test whether escitalopram would slow the brain atrophy in patients with mild to moderate AD over the 52-week period.
Eligibility Criteria
Inclusion Criteria
- Age:40~90 years
- Education:not illiterate
- Clinical Dementia Rating (CDR):0.5~2
- Modified Hachinski Ischemic Score (Rosen et al., 1979):less than 4
- Dementia according to DSM-IV criteria
- Probable Alzheimer's disease according to NINCDS-ADRDA criteria
- Current ongoing donepezil medication at stable doses (5 ~ 10 mg/day) for at least 2 months
Exclusion criteria
- Evidence of delirium, confusion or altered consciousness
- Evidence of Parkinson's disease, stroke, brain tumor and normal pressure hydrocephalus
- Evidence of infectious or inflammatory brain disease
- Evidence of serious cerebrovascular diseases
- Current major depressive disorder or other major psychiatric illnesses
- Evidence of serious or unstable medical illnesses which can significantly change cognitive state
- History of alcohol or other substance dependence
- Any antidepressant medications within the previous 4 weeks
- Absence of a reliable and cooperative collateral informant
- Any conditions which prohibit MRI scan, such as presence of pacemaker or cerebrovascular clip, and claustrophobia
- Evidence of focal brain lesions on MRI including lacunes and white matter hyperintensity lesions of grade 2 or more by Fazeka scale
Data sourced from ClinicalTrials.gov (NCT00702780). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.